Search
Antithrombin gamma
go.drugbank.com/drugs/DB16094InvestigationalAntithrombin gamma is under investigation in clinical trial NCT04182373 (KW-3357 Study in Patients With Early Onset Severe Preeclampsia).
Synonyms: Human antithrombin-iii (atiii, serpin c1) expressed in fucosyl transferase-negative chinese hamster ovary (cho) cells (glycoform gamma)Etokimab
go.drugbank.com/drugs/DB16661InvestigationalEtokimab is under investigation in clinical trial NCT03614923 (Etokimab in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps (Crswnp)).
Zagotenemab
go.drugbank.com/drugs/DB16674InvestigationalZagotenemab is under investigation in clinical trial NCT03518073 (A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease).
Lirentelimab
go.drugbank.com/drugs/DB16728InvestigationalLirentelimab is under investigation in clinical trial NCT04856891 (A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis).
Navicixizumab
go.drugbank.com/drugs/DB12634InvestigationalNavicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors).
Gefurulimab
go.drugbank.com/drugs/DB18928InvestigationalGefurulimab is under investigation in clinical trial NCT05556096 (Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis).
Epaminurad
go.drugbank.com/drugs/DB18973InvestigationalEpaminurad is under investigation in clinical trial NCT05815901 (A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients).
Orismilast
go.drugbank.com/drugs/DB19042InvestigationalOrismilast is under investigation in clinical trial NCT05190419 (Study to Assess the Efficacy and Safety of Orismilast in Psoriasis).
Letolizumab
go.drugbank.com/drugs/DB19072InvestigationalLetolizumab is under investigation in clinical trial NCT02273960 (Study to Evaluate Safety and Efficacy in Adult Subjects With ITP).
Surufatinib
go.drugbank.com/drugs/DB15106InvestigationalSurufatinib is under investigation in clinical trial NCT02588170 (Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors).